Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Body weight significantly influenced right heart function and survival in pulmonary arterial hypertension, with both extremes ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...